James D. Chambers, PhD, MPharm, MSc, professor of medicine at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, dives into why biosimilars contribute to a reduction in cost and increase in patient access, while highlighting challenges to adoption.
In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, comments on other concepts that are powering the company’s 2025 Supply Chain Trends Report, and how they could possibly change in 2026.
The latest news for pharma industry insiders.
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, discusses why the demand for supply chain transparency is continuing to gain momentum, while also explaining the role that track-and-trace initiatives are playing in that effort.
The latest news for pharma industry insiders.
The timing for the potential tax is yet to be determined, as the industry awaits to see the impact it could bring.
The latest news for pharma industry insiders.
A qualitative study examines how Medicaid telehealth reimbursement policies affect staffing and patient-centered care.
In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, comments on why she believes supply chain collaboration is becoming increasingly critical today.
The latest news for pharma industry insiders.
MedTech company issues a risk statement, noting fungal contamination.
The latest news for pharma industry insiders.
The company’s Mourenx plant in Southwest France aims to become an API network hub, with first supplies expected by next year.
In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, describes why these pharma supply chain stakeholders are vital in understanding meaningful clinical outcomes.
The latest news for pharma industry insiders.
These taxes on goods—with the potential to take effect in weeks or months—will vary by country, but rates could depend on regulations, industry subsidies, and other factors.
In the fourth part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, explains the value of FDA guidance documents for manufacturers, along with the areas of CGT development that would benefit most from standardization.
The latest news for pharma industry insiders.
The facilities are expected to offer pharma shipment support by addressing time and temperature-specific requirements.
In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, dives into specific areas where FDA investment could have the greatest impact in accelerating approval timelines.
The latest news for pharma industry insiders.
Trump raises the import tax to 25% on the former—while restoring the latter to 25%—in a move that could potentially take effect on March 4.
In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, discusses some of the other specific regulatory updates that drug developers be closely monitoring in the current landscape.
The agreement is centered around improving cell culture efficiency and CGT quality.
In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Jenna Dale, director of client relations at Cencora, explains the challenges associated with meeting the FDA’s 2025 CGT forecasted approval goal.
The latest news for pharma industry insiders.
A cohort study investigates the magnitude of lost coverage among pediatric patients, following the conclusion of the pandemic public health emergency.
In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Alex Guillen, global pharma and life sciences director at Tive, shares how the development of technology will help bolster the pharma logistics industry.
